These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31938827)

  • 41. Clostridioides (Clostridium) difficile infection burden in Japan: A multicenter prospective study.
    Kato H; Senoh M; Honda H; Fukuda T; Tagashira Y; Horiuchi H; Chiba H; Suzuki D; Hosokawa N; Kitazono H; Norisue Y; Kume H; Mori N; Morikawa H; Kashiwagura S; Higuchi A; Kato H; Nakamura M; Ishiguro S; Morita S; Ishikawa H; Watanabe T; Kojima K; Yokomaku I; Bando T; Toimoto K; Moriya K; Kasahara K; Kitada S; Ogawa J; Saito H; Tominaga H; Shimizu Y; Masumoto F; Tadera K; Yoshida J; Kikuchi T; Yoshikawa I; Watanabe T; Honda M; Yokote K; Toyokawa T; Miyazato H; Nakama M; Mahe C; Reske K; Olsen MA; Dubberke ER
    Anaerobe; 2019 Dec; 60():102011. PubMed ID: 30872073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clostridium difficile infection: current perspectives.
    Janka J; O'Grady NP
    Curr Opin Crit Care; 2009 Apr; 15(2):149-53. PubMed ID: 19578325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Asymptomatic and yet C. difficile-toxin positive? Prevalence and risk factors of carriers of toxigenic Clostridium difficile among geriatric in-patients.
    Nissle K; Kopf D; Rösler A
    BMC Geriatr; 2016 Nov; 16(1):185. PubMed ID: 27846818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
    Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
    PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics: A Prospective Cohort Study.
    Ianiro G; Murri R; Sciumè GD; Impagnatiello M; Masucci L; Ford AC; Law GR; Tilg H; Sanguinetti M; Cauda R; Gasbarrini A; Fantoni M; Cammarota G
    Ann Intern Med; 2019 Nov; 171(10):695-702. PubMed ID: 31683278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical review of Clostridium difficile infection: an update on treatment and prevention.
    Daniels LM; Kufel WD
    Expert Opin Pharmacother; 2018 Nov; 19(16):1759-1769. PubMed ID: 30220230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategies for prevention of Clostridium difficile infection.
    Dubberke E
    J Hosp Med; 2012 Mar; 7 Suppl 3():S14-7. PubMed ID: 22407995
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clostridium difficile Infection and Fecal Microbiota Transplant.
    Liubakka A; Vaughn BP
    AACN Adv Crit Care; 2016 Jul; 27(3):324-337. PubMed ID: 27959316
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate.
    Fischer M; Sipe BW; Rogers NA; Cook GK; Robb BW; Vuppalanchi R; Rex DK
    Aliment Pharmacol Ther; 2015 Aug; 42(4):470-6. PubMed ID: 26096320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of gut microbiota in Clostridium difficile infection.
    Samarkos M; Mastrogianni E; Kampouropoulou O
    Eur J Intern Med; 2018 Apr; 50():28-32. PubMed ID: 29428498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current management of Clostridioides (Clostridium) difficile infection in adults: a summary of recommendations from the 2017 IDSA/SHEA clinical practice guideline.
    Ma J; Dubberke E
    Pol Arch Intern Med; 2019 Mar; 129(3):189-198. PubMed ID: 30457126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients.
    Ro Y; Eun CS; Kim HS; Kim JY; Byun YJ; Yoo KS; Han DS
    Gut Liver; 2016 Jul; 10(4):581-6. PubMed ID: 27021503
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.
    Konturek PC; Koziel J; Dieterich W; Haziri D; Wirtz S; Glowczyk I; Konturek K; Neurath MF; Zopf Y
    J Physiol Pharmacol; 2016 Dec; 67(6):859-866. PubMed ID: 28195066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Toxigenic Clostridium difficile Colonization on the Risk of Subsequent C. difficile Infection in Intensive Care Unit Patients.
    Tschudin-Sutter S; Carroll KC; Tamma PD; Sudekum ML; Frei R; Widmer AF; Ellis BC; Bartlett J; Perl TM
    Infect Control Hosp Epidemiol; 2015 Nov; 36(11):1324-9. PubMed ID: 26223207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy.
    van Kleef E; Deeny SR; Jit M; Cookson B; Goldenberg SD; Edmunds WJ; Robotham JV
    Vaccine; 2016 Nov; 34(46):5562-5570. PubMed ID: 27727031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions.
    Ianiro G; Masucci L; Quaranta G; Simonelli C; Lopetuso LR; Sanguinetti M; Gasbarrini A; Cammarota G
    Aliment Pharmacol Ther; 2018 Jul; 48(2):152-159. PubMed ID: 29851107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clostridioides difficile: Current overview and future perspectives.
    Giles J; Roberts A
    Adv Protein Chem Struct Biol; 2022; 129():215-245. PubMed ID: 35305720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.